Pathophysiology of major depressive disorder: Mechanisms involved in etiology are not associated with clinical progression

Translational Psychiatry

Volumn 5, Issue 9, 2015, Pages

  Verduijn, J ^a   Milaneschi, Y ^a   Schoevers, R A ^b   Van Hemert, A M ^c   Beekman, A T F ^a   Penninx, B W J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; HYDROCORTISONE; INTERLEUKIN 6; SEROTONIN UPTAKE INHIBITOR; VITAMIN D; HYPOTHALAMUS HORMONE;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATHOPHYSIOLOGY; RISK; COHORT ANALYSIS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; INFLAMMATION; METABOLISM; MIDDLE AGED; NETHERLANDS; PATIENT ACUITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK FACTOR; STATISTICS;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; C-REACTIVE PROTEIN; COHORT STUDIES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMIC HORMONES; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; NETHERLANDS; PATIENT ACUITY; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; STATISTICS AS TOPIC; VITAMIN D;

EID: 84977763576     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.137     Document Type: Article

References (58)

1. Vogelzangs N, Duivis HE, Beekman a TF, Kluft C, Neuteboom J, Hoogendijk W et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry 2012; 2: e79.
2. Vreeburg Sa, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R et al. Major depressive disorder and hypothalamic-pituitary-Adrenal axis activity. Arch Gen Psychiatry 2009; 66: 617-626.
3. Molendijk ML, Bus Baa, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16: 1088-1095.
4. Milaneschi Y, Hoogendijk W, Lips P, Heijboer AC, Schoevers R, van Hemert AM et al. The association between low vitamin D and depressive disorders. Mol Psychiatry 2014; 19: 444-451.
5. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18: 595-606.
6. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-Analysis. Psychosom Med 2009; 71: 171-186.
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A metaanalysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
8. Liu Y, RC-M Ho, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-A) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-Analysis and meta-regression. J Affect Disord 2012; 139: 230-239.
9. Stetler C, Miller GE. Depression and hypothalamic-pituitary-Adrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011; 73: 114-126.
10. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464-468.
11. Manji HK, Quiroz Ja, Sporn J, Payne JL, Denicoff KA, Gray N et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression. Biol Psychiatry 2003; 53: 707-742.
12. Vrshek-Schallhorn S, Doane LD, Mineka S, Zinbarg RE, Craske MG, Adam EK. The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol Med 2013; 43: 483-493.
13. Bockting CLH, Lok A, Visser I, Assies J, Koeter MW, Schene AH. Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study. Psychiatry Res 2012; 200: 281-287.
14. Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. Neurobiology of depression: an integrated view of key findings. Int J Clin Pract 2007; 61: 2030-2040.
15. Molendijk ML, Spinhoven P, Polak M, Bus Baa, Penninx BWJH, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-Analyses on 179 associations (N = 9484). Mol Psychiatry 2014; 19: 791-800.
16. Birkenhäger TK, Geldermans S, Van den Broek WW, van Beveren N, Fekkes D. Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res 2012; 46: 285-289.
17. Anglin RES, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-Analysis. Br J Psychiatry 2013; 202: 100-107.
18. Ganji V, Milone C, Cody MM, McCarty F, Wang YT. Serum vitamin D concentrations are related to depression in young adult US population: the Third National Health and Nutrition Examination Survey. Int Arch Med 2010; 3: 29.
19. Cherniack EP, Troen BR, Florez HJ, Roos Ba, Levis S. Some new food for thought: The role of vitamin D in the mental health of older adults. Curr Psychiatry Rep 2009; 11: 12-19.
20. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009; 34: S265-S277.
21. Kalueff a V, Eremin KO, Tuohimaa P. Mechanisms of neuroprotective action of vitamin D3. Biochem 2004; 69: 738-741.
22. Gonella J, Hornbrook M, Louis D. Staging of disease. A case-mix measurement. JAMA 1984; 251: 637-644.
23. Scott J, Hickie IB, McGorry P. Pre-emptive psychiatric treatments: pipe dream or a realistic outcome of clinical staging models? Neuropsychiatry (London) 2012; 2: 263-266.
24. Agius M, Goh C, Ulhaq S, Mcgorry P. The Staging model in schizophrenia, and its clinical implications. Psychiatr Danub 2010; 22: 211-220.
25. Fusar-Poli P, Yung a R, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med 2014; 44: 17-24.
26. Kapczinski F, Magalhães PVS, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand 2014; 130: 354-363.
27. Hetrick SE, Parker a G, Hickie IB, Purcell R, Yung a R, McGorry PD. Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008; 77: 263-270.
28. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121-140.
29. Wittchen H-U. Reliability and validity studies of the WHO-Composite International Diagnostic (CIDI): a critical review. J Psychiatr Res 1994; 28: 57-84.
30. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486.
31. Lyketsos CG, Nestadt G, Cwi J, Heithoff K, Eaton WW. The life chart interview: a standardized method to describe the course of psychopathology. Int J Methods Psychiatr Res 1994; 4: 143-155.
32. Verduijn J, Milaneschi Y, van Hemert AM, Schoevers RA, Hickie IB, Penninx BWJH, et al. Clinical staging of major depressive disorder: an empirical exploration. J Clin Psychiatry 2015; 76: 1-9 (in press).
33. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003; 28: 916-931.
34. Bus BAA, Molendijk ML, Penninx BJWH, Buitelaar JK, Kenis G, Prickaerts J et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228-239.
35. Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin Chem 2012; 58: 543-548.
36. World Health Organization. The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. 2nd edn. WHO: Geneva, Switzerland, 2001.
37. World Health Organization Collaboration Centre for Drug Statistics Methodology Anatomical Therapeutic Chemical (ATC) Classification System. WHO: Oslo, Norway, 2007.
38. Valkanova V, Ebmeier KP, CRP AllanCL. IL-6 and depression: a systematic review and meta-Analysis of longitudinal studies. J Affect Disord 2013; 150: 736-744.
39. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121-1128.
40. Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM et al. Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endocrinol Metab 2010; 95: 3225-3233.
41. Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E. Vitamin D and common mental disorders in mid-life: Cross-sectional and prospective findings. Clin Nutr 2013; 32: 758-764.
42. Duclot F, Kabbaj M. Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. J Exp Biol 2015; 218: 21-31.
43. Karlovic D, Serretti A, Vrkic N, Martinac M, Marcinko D. Serum concentrations of CRP, IL-6, TNF-A and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 2012; 198: 74-80.
44. Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, Räsänen P, Leinonen M, Meyer-Rochow VB et al. The association between C-reactive protein levels and depression: results from the northern Finland 1966 birth cohort study. Biol Psychiatry 2006; 60: 825-830.
45. Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry 2012; 71: 15-21.
46. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry 2015; 20: 152-153.
47. NICE. Chronic Kidney Disease: Early Identification and Management of Chronic kidney disease in adults in primary and secondary care. NICE, London, UK, 2015.
48. Mcgorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders : a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.
49. Fava G, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993; 87: 225-230.
50. Penninx BWJH, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129.
51. Wiersma JE, JGFM Hovens, van Oppen P, Giltay EJ, van Schaik DJ, Beekman AT et al. The importance of childhood trauma and childhood life events for chronicity of depression in adults. J Clin Psychiatry 2009; 70: 983-989.
52. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
53. O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 2013; 30: 307-314.
54. Hickman RJ, Khambaty T, Stewart JC. C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination survey (NHANES) 1999-2004. J Behav Med 2014; 37: 621-629.
55. Hiles SA, Baker AL, de Malmanche T, Attia J. A meta-Analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012; 26: 1180-1188.
56. Vreeburg Sa, Hoogendijk WJG, DeRijk RH, van Dyck R, Smit JH, Zitman FG et al. Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. Psychoneuroendocrinology 2013; 38: 1494-1502.
57. Grønli O, Kvamme JM, Jorde R, Wynn R. Vitamin D deficiency is common in psychogeriatric patients, independent of diagnosis. BMC Psychiatry 2014; 14: 134.
58. Cosci F, Fava Ga. Staging of mental disorders: systematic review. Psychother Psychosom 2013; 82: 20-34.